Two Schemes Response in Multiple Myeloma

Launched by HOSPITAL GENERAL DE MEXICO · Feb 26, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Two Schemes Response in Multiple Myeloma," is looking into how effective different treatment combinations are for patients with multiple myeloma, a type of blood cancer, before they undergo stem cell transplantation. The study is examining the medical records of patients who received either the VTD or TD combination of drugs as their first treatment. The goal is to understand how well these treatment schemes work and how they affect patients' responses to therapy.

To be eligible for this study, patients should be between 65 and 74 years old and have medical records that show they were suitable for a stem cell transplant based on their overall health. They must have also received a drug combination treatment. However, patients with incomplete medical records or those who could not continue treatment due to financial or distance issues will not be included. This study is currently recruiting participants, and those involved can expect their previous treatment outcomes to be reviewed to help improve future care for multiple myeloma patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs.
• Exclusion Criteria:
• • Incomplete clinical records
• • Clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues
• • Clinical records of patients who presented severe sepsis before the beginning of either treatment